DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy

Cynthia Bernier(Occupational Cancer Research Centre), Anne Roulston(Goodman (Japan)), Paul Savage(Unknown), Michel Gravel(University of Lübeck), Ahmed Soliman(Goodman (Japan)), Peter M. Siegel(L'Oréal (France)), Matthew Dankner(McGill University), Morag Park(McGill University Health Centre), Gordon C. Shore(McGill University), Kevin Petrecca(McGill University Health Centre)
Anti-Cancer Drugs
June 7, 2018
Cited by 22


Related Papers